BeOne Medicines (BEIGF) Cost of Revenue (2017 - 2026)

BeOne Medicines (BEIGF) has 10 years of Cost of Revenue data on file, last reported at $167.2 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $167.2 million, up 1.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $670.8 million (up 5.77% YoY), and the FY2025 annual result was $668.5 million, up 12.53% from the prior year.
• Cost of Revenue rose to $167.2 million in Q1 2026 per BEIGF's latest filing, from $142.4 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $196.5 million in Q3 2025 and troughed at $65.2 million in Q1 2022.
• A 5-year average of $123.3 million and a median of $124.9 million in 2024 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue soared 99.59% in 2022, then dropped 11.3% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $73.5 million in 2022, then jumped by 43.95% to $105.8 million in 2023, then jumped by 51.71% to $160.6 million in 2024, then dropped by 11.3% to $142.4 million in 2025, then rose by 17.41% to $167.2 million in 2026.
• Business Quant data shows BEIGF's Cost of Revenue at $167.2 million in Q1 2026, $142.4 million in Q4 2025, and $196.5 million in Q3 2025.